Lilly Oncology to Disclose New Pipeline Data at ASCO

The 48th Annual Meeting of the American Society of Clinical Oncology is to take place in June. Lilly early-stage pipeline molecules will be featured at oral presentations at ASCO with two first-in-human Phase I studies.

Eli Lilly and Company will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 – 5, 2012.

Lilly Oncology has more than 30 molecules in early- and late-stage development to treat various types of cancer. 

Lilly early-stage pipeline molecules will be featured at oral presentations at ASCO with two first-in-human Phase I studies, one on its oral NOTCH inhibitor LY900009 and the other for its oral p38 MAPK inhibitor LY2228820 dimesylate, both being evaluated in patients with advanced cancer. Another oral presentation will highlight LY2780301, an oral P70S6K/AKT inhibitor, a first-in-human Phase I study of patients with refractory sol